Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of TA : ACR and /or Ishikawa modified Sharma criteria of TA~* Age of 18 years or older~* Willing to use an effective means of birth control throughout the study~Exclusion Criteria:~* Patients immunosuppressive treatment or biologics other than steroids 4 months before~* Evidence of active infection (including chronic infection)~* HIV infected, hepatitis C infected, or a positive hepatitis B surface antigen~* History of any malignant neoplasm except adequately treated basal or squamous cell carcinoma of the skin or solid tumors treated with curative therapy and disease-free for at least 5 years~* Inability to provide informed consent~* Cytopenia, as defined by platelet count \< 100 × 109/L (100,000/mm3), hemoglobin \< 85 g/L (8.5 g/dL; 5.3 mmol/L), absolute neutrophil count \< 2.0 × 109/L (2000/mm3), absolute lymphocyte count \< 0.5 × 109/L (500/mm3)~* Insufficient liver function~* Insufficient kidney function, as defined by a serum creatinine of more than 3 mg/dL or creatinine clearance of 20 ml/min or less~* Positive tuberculin skin test and/or positive Quantiferon~* Radiographic evidence suggestive of tuberculosis~* Contraindication to and precaution in use of Tocilizumab according to the summary product description~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- TOCILIZUMAB MONTHLY DURING 6 (Type: EXPERIMENTAL): intravenous injection, 8 mg/kg, monthly during 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).